Last reviewed · How we verify
NCT02757989
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk
NA trial testing transplantation in MDS in 79 participants. Completed in 7 June 2024.
7 June 2024
Quick facts
| Lead sponsor | Groupe Francophone des Myelodysplasies |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 79 |
| Start date | 31 May 2016 |
| Primary completion | 7 June 2024 |
| Estimated completion | 7 June 2024 |
| Sites | 37 locations across France |
Drugs / interventions tested
- transplantation
Conditions studied
- MDS — all drugs for MDS →
Sponsor
Groupe Francophone des Myelodysplasies — full company profile →
Who can join
Adults 18 to 69, any sex, with MDS. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Comparison of survival in patients with or without a matched donor at 36 months
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Lower risk but high risk.
DeZern AE. · · 2021 · cited 10× · PMID 34889376 · DOI 10.1182/hematology.2021000277 -
Lower-risk myelodysplastic syndromes: Current treatment options for anemia.
Meunier M, Park S. · · 2022 · cited 9× · PMID 36467818 · DOI 10.1002/jha2.523 -
Low-risk MDS-A spotlight on precision medicine for <i>SF3B1-</i>mutated patients.
Burke S, Chowdhury O, Rouault-Pierre K. · · 2025 · cited 1× · PMID 40124717 · DOI 10.1002/hem3.70103 -
Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability.
Sébert M, Thepot S, Cluzeau T, Duployez N, et al · · 2026 · PMID 41061188 · DOI 10.1182/bloodadvances.2025017035
Verify or expand the search:
- PubMed search for NCT02757989
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for MDS
Currently open trials in the same condition.
- NCT07328191 — Quality of Life-Guided Transfusion in Refractory MDS or AML · NA · recruiting
- NCT06717958 — Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute M · Phase 2 · recruiting
- NCT06972641 — Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation · Phase 2, PHASE3 · recruiting
- NCT07006025 — A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS) · Phase 1 · recruiting
- NCT06895538 — Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy · recruiting
Other Groupe Francophone des Myelodysplasies trials
Trials by the same sponsor.
- NCT05226455 — Venetoclax in Patients With MDS or AML in Relapse After AHSCT · Phase 1, PHASE2 · active not recruiting
- NCT05181735 — Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA · Phase 1, PHASE2 · recruiting
- NCT04857645 — ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients · Phase 2 · completed
- NCT04827719 — BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS · Phase 2 · completed
- NCT04273802 — CPX-351 in Higher Risk Myelodysplastic Syndromes · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02757989 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Groupe Francophone des Myelodysplasies
- Last refreshed: 2 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02757989.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing